Quarterly report pursuant to Section 13 or 15(d)

Royalty and Commercial Payment Purchase Agreements (Tables)

v3.23.3
Royalty and Commercial Payment Purchase Agreements (Tables)
9 Months Ended
Sep. 30, 2023
Royalty and Commercial Payment Purchase Agreements  
Summary of royalty and commercial payment receivable activities

The following table summarizes the royalty and commercial payment receivable activities during the nine months ended September 30, 2023 (in thousands):

Short-Term

Long-Term

Balance at January 1, 2023

    

$

2,366

$

63,683

Acquisition of royalty and commercial payment receivables:

Aptevo

 

 

9,650

LadRx

6,000

Receipt of royalty and commercial payments:

Affitech

(7,284)

Aptevo

(1,144)

Impairment of royalty and commercial payment receivables:

Bioasis

(1,575)

Reclassification to short-term royalty and commercial payment receivables:

Affitech

4,918

(4,918)

Recognition of contingent consideration:

Affitech

3,000

Balance at September 30, 2023

$

$

74,696